Phase 1/2 Clinical Trials
146 trials are at Phase 1/2 in the index.
Trials (146)
- Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer Phase 1/2 · NYU Langone Health
- Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma Phase 1/2 · University of Pennsylvania
- Multiple CAR-T Cell Therapy Targeting AML Phase 1/2 · Shenzhen Geno-Immune Medical Institute
- Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors Phase 1/2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Phase 1/2 · University of Southern California
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML Phase 1/2 · The Korean Society of Pediatric Hematology Oncology
- APG-115 in Salivary Gland Cancer Trial Phase 1/2 · University of Michigan Rogel Cancer Center
- Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer. Phase 1/2 · Peking University Third Hospital
- To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. Phase 1/2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Phase 1/2 · Mayo Clinic
- DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation Phase 1/2 · Universitair Ziekenhuis Brussel
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Phase 1/2 · Fred Hutchinson Cancer Center
- AMT-116 in Combination With AK112 in Patients With Lung Cancer Phase 1/2 · Multitude Therapeutics Inc.
- A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer Phase 1/2 · Array BioPharma
- A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Phase 1/2 · Regeneron Pharmaceuticals
- S 81694 Plus Paclitaxel in Metastatic Breast Cancer Phase 1/2 · Institut de Recherches Internationales Servier
- Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?! Phase 1/2 · Ahmed Saad
- Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). Phase 1/2 · Johns Hopkins University
- Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain Phase 1/2 · Memorial Sloan Kettering Cancer Center
- ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 1/2 · Vanderbilt-Ingram Cancer Center
- Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/2 · Emory University
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) Phase 1/2 · M.D. Anderson Cancer Center
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase 1/2 · Johnny Kao
- Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Phase 1/2 · M.D. Anderson Cancer Center
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Phase 1/2 · Northwestern University
- A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy Phase 1/2 · Cellbion Co., Ltd.
- Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 Phase 1/2 · Memorial Sloan Kettering Cancer Center
- Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Phase 1/2 · University Children's Hospital Tuebingen
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors Phase 1/2 · Lepu Biopharma Co., Ltd.
- Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 1/2 · BioMimetix JV, LLC
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer Phase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Efficacy of Interleukin-2 in Triple Negative Breast Cancer Phase 1/2 · Nova Scotia Health Authority
- Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer Phase 1/2 · Yonsei University
- Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection Phase 1/2 · Radboud University Medical Center
- Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Phase 1/2 · Novartis Pharmaceuticals
- Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer Phase 1/2 · Dizal Pharmaceuticals
- A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer Phase 1/2 · Nykode Therapeutics ASA
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM Phase 1/2 · GlaxoSmithKline
- Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Phase 1/2 · City of Hope Medical Center
- A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma Phase 1/2 · Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/2 · SUNHO（China）BioPharmaceutical CO., Ltd.
- A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer Phase 1/2 · Beta Pharma (Suzhou) Co., Ltd.
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 1/2 · Vadim S Koshkin
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Phase 1/2 · GlaxoSmithKline
- Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome Phase 1/2 · Florian Strasser, MD ABHPM
- A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer Phase 1/2 · Asan Medical Center
- A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Phase 1/2 · Hoffmann-La Roche
- Investigation of a Behavioral Substitute for Sunbathing Phase 1/2 · University of Massachusetts, Worcester
- First-In-Human Study of KHN922 for Injection Phase 1/2 · Chengdu Kanghong Biotech Co., Ltd.
- Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Phase 1/2 · M.D. Anderson Cancer Center
Related landscapes
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.